Initially, Blue Earth Therapeutics is building a portfolio of precision-targeted radiopharmaceuticals focused on prostate cancer. In the future, it will expand to additional diseases in oncology.
Also, the subsidiary has exclusive rights to therapeutic applications of radiohybrid prostate-specific membrane antigen radiopharmaceutical technology. David Gauden, PhD, is CEO of Blue Earth Therapeutics.
Copyright © 2022 AuntMinnie.com